Ed Addison
Ed Addison
CEO, Serial Entrepreneur and Board Member of Disruptive New Technology Ventures; Author/Speaker, and Adjunct Professor
Raleigh-Durham, North Carolina Area

  • Focus: Contributions are valued by peers
  • Accountability: Thoroughly contributes in all areas
  • Sense of Urgency: Consistently responds in a timely fashion
  • Team: Frequently supports and responds to peers

Awards earned:





Level: LEVEL 02

12 month points: 261 ptsView details

Total points: 261 pts

Precision Medicine 6
Machine Learning 3
Molecular Biology
Life Sciences
Venture Capital
Electrical Engineering
Stochastic Processes
Intellectual Property
Business Law
Artifical Intelligence
Neural Networks
Business Development
Public Speaking
Quantum Computing
University Teaching
Operations Management
complex systems
General Aviation
Government Contracting
Speech Recognition
Natural Language Processing
Signal Processing
Data Science
Business Intelligence
general management
Block Chain
Cloud Computing


Ed Addison, is Chairman and CEO of Cloud Pharmaceuticals, an established leader in Artificial Intelligence based drug design and development located in Research Triangle Park. Cloud Pharmaceuticals has new drugs in development for cancer, inflammation and rare diseases. Ed is also Chairman of 57-on-Fire, a clinical stage rare disease pharmaceutical company, and he serves on several other boards. His expertise is in deploying exponential technologies in health care, life sciences, artificial intelligence enabled ventures, and information technology.

With a technical background in Artificial Intelligence and a strong business development and capital raising background, Ed is an established serial entrepreneur of disruptive ventures. Ed started 7 companies, funded 5 of them and exited 3. He has twice been named "Entrepreneur of the Year". He has advised 7 venture capital funds and over 20 early stage ventures.

Ed is an adjunct professor of business and entrepreneurship for MBA and engineering students. He has previously taught Artificial Intelligence, Computer Science, and Bioinformatics for several universities including NC State University, Stevens Institute of Technology and Johns Hopkins University. Ed holds a BSEE from Virginia Tech, two MS degrees from Johns Hopkins, an MBA from Duke University, and an 'online' law degree from Concord Law School at Perdue University. He completed a sabbatical year at MIT in Artificial Intelligence.



Cloud Pharmaceuticals, Inc.

January 2011 - Present

Ed is cofounder, CEO and Chairman of Cloud Pharmaceuticals, an established leader in AI based drug discovery. Cloud's mission is to efficiently and rapidly develop new drugs using artificial intelligence and cloud computing using technology originally developed at Duke University. The company is currently developing new drugs for cancer, inflammation, rare diseases, and many others and has stakes in more than 20 new drug programs. Cloud Pharmaceuticals' discovery platform has achieved demonstrated success on all of its drug design programs.

Cloud Pharmaceuticals was founded by the confluence of predecessor venture TeraDisc LLC on high performance computing with the research work in the department of chemistry at Duke University. Initially, the company used Virginia Tech's System X supercomputer until it was surpassed by cloud computing. Microsoft provided the initial seed funding for the company, and the University of Florida, via its Gatorade fund, provided the funding for the initial proof of concept in the laboratory.

Adjunct Faculty in New Business Ventures and Entrepreneurship

Jack Welch Management Institute

September 2017 - Present

Ed teaches MBA subjects including New Business Ventures and Entrepreneurship in the MBA program at JWMI. This program is the #18 global online MBA and the fastest growing MBA in the world.


North Carolina State University

August 2010 - Present

Ed Addison is training the next generation of entrepreneurs and product managers at NC State University. He teaches graduate courses and industry courses in new product launches, product management, innovation, entrepreneurship and business topics for engineers. He has authored a book called "Leveraging the Horizon" on new venture creation and he is currently authoring a book on Artificial Intelligence in Healthcare. Ed is also a business plan reviewer at multiple universities.

Managing Partner

Infinity Venture Group

December 2000 - Present

Ed Addison has been a serial entrepreneur since 1990. As a managing partner for Infinity Venture Group, he consults with, advises and takes board roles with new start up companies, particularly high tech ventures spinning out of university settings. Ed is "hands on" with capital raising campaigns. Ed is an established leader for the launch of new high technology products.

Ed is Chairman of 57-on-Fire, a clinical stage rare disease pharmaceutical venture; adviser to pharmacogenomics venture Parallel Profile; adviser to UK-based mobile app venture Global Source Group; and is actively engaged in business development for drug safety company Drug Logic. In addition, Ed is working on a committee of medical professionals to define and launch the "medical school of the future".

Ed previously worked with TeraDiscoveries (a life sciences high performance computing company), Inclinix ( a search engine based clinical trials recruiting company), BioSequent (a bioinformatics and AI company), BioFortis (a LIMS company), and Lessac Technologies (a voice synthesis company, where he was co founder and inventor).

He was previously a member of the executive investment committee at venture capital firm Next Generation Funds, advisor to Incube8 and Maryland TAP business incubator programs, a limited partner in venture funds Boulder Fund 1 &2, and Sands Brothers Fund 2, and was a business plan judge for Johns Hopkins University, UNCW and Duke University.